Search Results 1031-1040 of 18648 for Relapse
Teclistamab-cqyv injection is used to treat relapsed (cancer that has come back) or refractory (cancer that did not respond to treatment) multiple myeloma ...
Molecular predictors of response and survival in patients with relapsed/refractory acute myeloid leukemia following venetoclax plus hypomethylating agent ...
Additionally, no studies to date have investigated this during intralesional tumor resections. NL-201 in Patients With Relapsed or Refractory Cancer. Rochester, ...
... relapsed/refractory non-Hodgkin lymphoma: A multicenter consensus approach. Am J Hematol. 2024 Jan; 99 (1):124-134 Epub 2023 Nov 11. View PubMed; Gaulin C ...
Expertise in management of relapsed/refractory plasma cell dyscrasias; Development of early and late-phase clinical trials for plasma cell dyscrasias ...
This phase II trial studies how well giving ruxolitinib phosphate (oral JAK inhibitor INCB18424) works in treating patients with relapsed or refractory ...
... , Mayo Clinic treats pediatric patients with primary and recurrent rhabdomyosarcoma, offering a cutting-edge treatment option for relapsed disease.
... Relapsed/Refractory Non-Hodgkin Lymphoma. Clin Lymphoma Myeloma Leuk ... Incidence of Central Nervous System Relapse in Primary Mediastinal Large B ...
... relapse prevention. Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health ...
... relapse) and not all survive. Previous research has identified features of FHWT that are associated with higher or lower risks of relapse. The term "risk ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.